The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interlesional response assessment with 18F-sodium fluoride (18F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).
 
Christos Kyriakopoulos
Consulting or Advisory Role - Exelixis
Speakers' Bureau - The France Foundation
Research Funding - Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Esanik (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inovio Pharmaceuticals (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Oncolys BioPharma (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
Anna C. Ferrari
Stock and Other Ownership Interests - Exelixis (I); TAKEDA
Consulting or Advisory Role - Astellas Pharma; Auven Therapeutics; Bayer; Medivation
Research Funding - Dendreon (Inst); Novartis (Inst); Orion (Inst); Oxford Biomedica (Inst); SOTIO (Inst)
 
Scott Perlman
Research Funding - GE Healthcare Progenics
Other Relationship - Pfizer
 
Tina M. Mayer
Consulting or Advisory Role - AstraZeneca; Beacon Bioscience/ICON Medical; Novartis
Research Funding - Merck (Inst); Sotio (Inst)
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Xencor (Inst)
 
Katharina Modelska
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
William Duggan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Robert Jeraj
Stock and Other Ownership Interests - AIQ Solutions
Research Funding - GE Healthcare
Patents, Royalties, Other Intellectual Property - Several Wisconsin Alumni Research Foundation patents
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Exelixis; Janssen; Novartis; Tricon Pharmaceuticals
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)